Cytokinetics vs Repligen
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Cytokinetics and Repligen side by side, using each oneβs latest annual report. Here is what stands out:
- Repligen is the larger business, with $738M of revenue in fiscal 2025 against $88.0M for Cytokinetics, about 8.4 times as much.
- Cytokinetics grew revenue faster (376.6%, against 16.4%).
- Repligen kept more of each dollar of sales as operating profit (7.5% operating margin, against β695.4%).
- Repligen turned more of its sales into free cash flow (12.7% FCF margin, against β607.5%).
Who comes out ahead
Of the 5 measures where higher (or lower) is clearly better, how many each company leads.
Cytokinetics
CYTK
1/5
Revenue growth
Repligen
RGEN
4/5
5-year growthOperating marginNet marginFCF margin
Side by side
Best in the row
| Latest fiscal year | CYTK FY25 | RGEN FY25 |
|---|---|---|
| Size | ||
| Market cap | β | β |
| Revenue | $88.0M | $738M |
| Free cash flow | β$535M | $93.9M |
| Net income | β$785M | $48.9M |
| Growth | ||
| Revenue growth | 376.6% | 16.4% |
| 5-year growth | 9.5% | 15.1% |
| Share count change | β | β |
| Profitability | ||
| Gross margin | β | 52.3% |
| Operating margin | β695.4% | 7.5% |
| Net margin | β891.6% | 6.6% |
| FCF margin | β607.5% | 12.7% |
| Return on capital | β | 2.4% |
| Return on equity | β | 2.4% |
| Balance sheet | ||
| Net debt | β$912M | β$225M |
| Net debt / EBITDA | β | β1.7x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | β | β |
| Piotroski F-score | β | β |
Ten years
Revenue
FY16
CYTK $106M
RGEN $105M
FY17
CYTK $13.4M
RGEN $141M
FY18
CYTK $31.5M
RGEN $194M
FY19
CYTK $26.9M
RGEN $270M
FY20
CYTK $55.8M
RGEN $366M
FY21
CYTK $70.4M
RGEN $671M
FY22
CYTK $94.6M
RGEN $802M
FY23
CYTK $7.5M
RGEN $632M
FY24
CYTK $18.5M
RGEN $634M
FY25
CYTK $88.0M
RGEN $738M
CYTK
RGEN
Operating margin
FY16
CYTK 17.6%
RGEN 15.3%
FY17
CYTK β848.3%
RGEN 9.9%
FY18
CYTK β282.3%
RGEN 13.4%
FY19
CYTK β368.0%
RGEN 13.4%
FY20
CYTK β168.3%
RGEN 19.1%
FY21
CYTK β264.5%
RGEN 24.9%
FY22
CYTK β342.8%
RGEN 28.0%
FY23
CYTK β6,589.7%
RGEN 7.5%
FY24
CYTK β2,902.7%
RGEN β5.5%
FY25
CYTK β695.4%
RGEN 7.5%
CYTK
RGEN
Free cash flow
FY16
CYTK $35.4M
RGEN $3.2M
FY17
CYTK β$105M
RGEN $12.0M
FY18
CYTK β$102M
RGEN $22.1M
FY19
CYTK β$93.5M
RGEN $48.7M
FY20
CYTK β$2.1M
RGEN $40.2M
FY21
CYTK β$191M
RGEN $51.9M
FY22
CYTK β$311M
RGEN $87.3M
FY23
CYTK β$416M
RGEN $77.7M
FY24
CYTK β$400M
RGEN $150M
FY25
CYTK β$535M
RGEN $93.9M
CYTK
RGEN
Return on capital
FY16
CYTK β
RGEN 15.2%
FY17
CYTK β
RGEN 4.3%
FY18
CYTK β
RGEN 3.9%
FY19
CYTK β
RGEN 4.6%
FY20
CYTK β
RGEN 7.7%
FY21
CYTK β
RGEN 11.4%
FY22
CYTK β
RGEN 12.4%
FY23
CYTK β
RGEN 1.7%
FY24
CYTK β
RGEN β1.6%
FY25
CYTK β
RGEN 2.4%
CYTK
RGEN
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.